Zytostatikainduzierte Polyneuropathien

 

 Buy Article Permissions and Reprints

Zusammenfassung

Im Rahmen maligner Erkrankungen kommt es häufig zu einer Schädigung neuromuskulärer Strukturen. Die ursächlichen pathophysiologischen Mechanismen sind jedoch vielschichtig. Neben der direkten Infiltration durch neoplastische Zellen kann das Nervengewebe paraneoplastisch geschädigt werden. Zusammengenommen führt dies bei ca. 2,5 % der Patienten mit Karzinomen oder Lymphomen zu einer klinisch manifesten sensomotorischen Polyneuropathie. Weitaus häufiger tritt die Neuropathie als Nebenwirkung einer zytostatischen Therapie mit Taxoiden, Vinca-Alkaloiden oder platinhaltigen Substanzen (Cisplatin) auf. Pathophysiologisch liegt der Neurotoxizität eine Behinderung des axonalen Transportes mit nachfolgender Gewebsschädigung zugrunde. In Abhängigkeit des verwendeten Pharmakons ergeben sich unterschiedlich starke Schädigungen der einzelnen Faserqualitäten. Unter einer Therapie mit Cisplatin entwickelt sich eine rein sensible Polyneuropathie mit einem frühzeitigen Verlust des Vibrationsempfindens. Elektrophysiologische und somatosensorische Untersuchungen wiesen eine Schädigung der myelinisierten und unmyelinisierten Afferenzen nach. Neben der Schädigung sensibler Fasern tritt unter Taxol, insbesondere nach hohen Kumulativdosen, eine Schädigung der motorischen Fasern auf. Klinisch stehen jedoch Parästhesien und Störungen der Mechanorezeption sowie Propriozeption im Vordergrund. Durch Vinca-Alkaloide induzierte Polyneuropathien manifestieren sich häufig in schmerzhaften Parästhesien. Zusätzlich können sensible Störungen sowie Paresen insbesondere der distalen Muskulatur bestehen. Elektrophysiologische Daten bestätigen das klinische Bild. Das Ausmaß der Nervenschädigung wird durch die verabreichte Gesamtdosis des jeweiligen Zytostatikums beeinflusst. Bei schweren Verläufen können die neurotoxischen Nebenwirkungen einen Abbruch der Chemotherapie notwendig machen. Versuche, durch den Einsatz neuroprotektiver Substanzen eine Reduktion der Nebenwirkungen zu erreichen, waren bis jetzt nur eingeschränkt erfolgreich.

Chemotherapy Induced Neuropathy

An underlying carcinoma is an important differential diagnosis in peripheral neuropathy, but the pathophysiological mechanisms are different. In addition to direct infiltration of nerve tissue paraneoplastic processes are posssible. The prevalence of a clinically detectable peripheral neuropathy in cancer patients is approximately 2.5 %. More frequently peripheral neuropathy occurs as a side effect of zytostatic treatment with taxoides, vinca-alcaloides or cisplatin. Pathophysiologically these drugs interact with neurotubules and microtubules which results in a block of fast axoplasmic transport followed by axonal nerve degeneration. The extent and the clinical manifestation of these drug-induced neuropathies depend on the substance and the total dosage. Cisplatin-induced neuropathy is restricted to sensory fibres. The earliest clinical sign is the loss of vibration sensation. Hypaesthesia, the loss of vibration sensation and sense of position are also side effects of taxoid therapy. In addition, involvement of motor fibres can be observed especially after administration of high doses. The occurrence of sensory deficits, painful paraesthesias and weakness is characteristic for a vinca alkaloid-induced neuropathy. The early detection of peripheral neuropathy due to cancer chemotherapy is important, because it is a potentially dose-limiting complication. Until now attemps to reduce neurotoxicity by administration of neuroprotective substances had only limited success.

Literatur

• 1 Hughes R, Sharrack B, Rubens R. Carcinoma and the peripheral nervous system.  J Neurol. 1996;  243 371-376
  PubMedGoogle Scholar
• 2 Currie S, Henson R A, Morgan H G. et al . The incidence of the non-metastatic neurological syndromes of obscure origin in the reticuloses.  Brain. 1970;  93 629-640
  PubMedGoogle Scholar
• 3 Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma.  J Neurol Neurosurg Psychiatry. 1948;  11 73
  CrossrefPubMedGoogle Scholar
• 4 Graus F, Cordon-Cardo C, Posner J B. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer.  Neurology. 1985;  35 538-543
  CrossrefPubMedGoogle Scholar
• 5 Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from platinum electrodes.  Nature. 1965;  205 698-699
  CrossrefPubMedGoogle Scholar
• 6 Higby D J, Wallace H J, Albert D. et al . Diamminodichloroplatinum in the chemotherapy of testicular tumors.  J Urol. 1974;  112 100-104
  PubMedGoogle Scholar
• 7 Hayes D M, Cvitkovic E, Golbey R B. et al . High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.  Cancer. 1977;  39 1372-1381
  PubMedGoogle Scholar
• 8 Hartmann J T, Kanz L, Bokemeyer C. Diagnosis and treatment of patients with testicular germ cell cancer.  Drugs. 1999;  58 257-281
  PubMedGoogle Scholar
• 9 Bohm S, Oriana S, Spatti G. et al . Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma.  Oncology. 1999;  57 115-120
  PubMedGoogle Scholar
• 10 Wasserheit C, Frazein A, Oratz R. et al . Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.  J Clin Oncol. 1996;  14 1993-1999
  PubMedGoogle Scholar
• 11 Pronk L C, Schellens J H, Planting A S. et al . Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.  J Clin Oncol. 1997;  15 1071-1079
  PubMedGoogle Scholar
• 12 Kedar A, Cohen M E, Freeman A I. Peripheral neuropathy as a complication of cis- dichlorodiammineplatinum (II) treatment: a case report.  Cancer Treat Rep. 1978;  62 819-821
  PubMedGoogle Scholar
• 13 Thompson S W, Davis L E, Kornfeld M. et al . Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.  Cancer. 1984;  54 1269-1275
  CrossrefPubMedGoogle Scholar
• 14 Roelofs R I, Hrushesky W, Rogin J. et al . Peripheral sensory neuropathy and cisplatin chemotherapy.  Neurology. 1984;  34 934-938
  CrossrefPubMedGoogle Scholar
• 15 Hansen S W, Helweg-Larsen S, Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer.  J Clin Oncol. 1989;  7 1457-1461
  PubMedGoogle Scholar
• 16 Mollman J E. Cisplatin neurotoxicity (editorial;).  N Engl J Med. 1990;  322 126-127
  PubMedGoogle Scholar
• 17 Krarup-Hansen A, Fugleholm K, Helweg-Larsen S. et al . Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function.  Brain. 1993;  116 1017-1041
  PubMedGoogle Scholar
• 18 Rosenfeld C S, Broder L E. Cisplatin-induced autonomic neuropathy.  Cancer Treat Rep. 1984;  68 659-660
  PubMedGoogle Scholar
• 19 Boogerd W, ten Bokkel Huinink W W, Dalesio O. et al . Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement.  J Neurooncol. 1990;  9 255-263
  CrossrefPubMedGoogle Scholar
• 20 Schweitzer V G. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents.  Laryngoscope. 1993;  103 1-52
  PubMedGoogle Scholar
• 21 Schweitzer V G. et al . Visual system toxicity following intra-arterial chemotherapy.  Neurology. 1988;  38 284-289
  PubMedGoogle Scholar
• 22 Alberts D S, Noel J K. Cisplatin-associated neurotoxicity: can it be prevented?.  Anticancer Drugs. 1995;  6 369-383
  PubMedGoogle Scholar
• 23 Mollman J E, Hogan W M, Glover D J. et al . Unusual presentation of cis-platinum neuropathy.  Neurology. 1988;  38 488-490
  PubMedGoogle Scholar
• 24 Hovestadt A, van der Burg M E, Verbiest H B. et al . The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.  J Neurol. 1992;  239 143-146
  PubMedGoogle Scholar
• 25 Yamamoto M, Kachi T, Yamada T. et al . Sensory conduction study of cisplatin neuropathy: preservation of small myelinated fibers.  Intern Med. 1997;  36 829-833
  PubMedGoogle Scholar
• 26 Daugaard G K, Petrera J, Trojaborg W. Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin.  Acta Neurol Scand. 1987;  76 86-93
  PubMedGoogle Scholar
• 27 Tomiwa K, Nolan C, Cavanagh J B. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry.  Acta Neuropathol. 1986;  69 295-308
  CrossrefPubMedGoogle Scholar
• 28 Cavaletti G, Bogliun G, Marzorati L. et al . Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer.  Anticancer Res. 1994;  14 1287-1292
  PubMedGoogle Scholar
• 29 Cavaletti G, Marzorati L, Bogliun G. et al . Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity.  Cancer. 1992;  69 203-207
  CrossrefPubMedGoogle Scholar
• 30 Barajon I, Bersani M, Quartu M. et al . Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy.  Exp Neurol. 1996;  138 93-104
  CrossrefPubMedGoogle Scholar
• 31 Gao W Q, Dybdal N, Shinsky N. et al . Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy.  Ann Neurol. 1995;  38 30-37
  CrossrefPubMedGoogle Scholar
• 32 Boekelheide K, Arcila M E, Eveleth J. Cis-diaminedichloroplatinum (II) (cisplatin) alters microtubule assembly dynamics.  Toxicol Appl Pharmacol. 1992;  116 146-151
  CrossrefPubMedGoogle Scholar
• 33 Verdu E, Vilches J J, Rodriguez F J. et al . Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice.  Muscle Nerve. 1999;  22 329-340
  PubMedGoogle Scholar
• 34 Gerard B, Bleiberg H, Van Daele D. et al . Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer.  Anticancer Drugs. 1998;  9 301-305
  PubMedGoogle Scholar
• 35 Extra J M, Marty M, Brienza S. et al . Pharmacokinetics and safety profile of oxaliplatin.  Semin Oncol. 1998;  25 13-22
  PubMedGoogle Scholar
• 36 Adelsberger H, Quasthoff S, Grosskreutz J. et al . The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.  Eur J Pharmacol. 2000;  406 25-32
  CrossrefPubMedGoogle Scholar
• 37 Wani M C, Taylor H L, Wall M E. et al . Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.  J Am Chem Soc. 1971;  93 2325-2327
  CrossrefPubMedGoogle Scholar
• 38 Bissery M C, Guenard D, Gueritte-Voegelein F. et al . Experimental antitumor activity of taxotere (RP 56 976, NSC 628 503), a taxol analogue.  Cancer Res. 1991;  51 4845-4852
  PubMedGoogle Scholar
• 39 Benjapibal M, Kudelka A P, Vasuratna A. et al . Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer.  Anticancer Drugs. 1998;  9 577-579
  PubMedGoogle Scholar
• 40 Luck H J, Scholz U, Kuhnle H. et al . UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer.  Oncology (Huntingt). 1999;  13 74-76
  PubMedGoogle Scholar
• 41 Eisenhauer E A, Vermorken J B. The taxoids. Comparative clinical pharmacology and therapeutic potential.  Drugs. 1998;  55 5-30
  PubMedGoogle Scholar
• 42 Forastiere A A, Rowinsky E K, Chaudry V. Phase I trial of taxol and cisplatin plus G-CSF in solid tumors.  Proc Am Soc Clin Oncol. 1992;  11 117
  PubMedGoogle Scholar
• 43 Lipton R B, Apfel S C, Dutcher J P. et al . Taxol produces a predominantly sensory neuropathy.  Neurology. 1989;  39 368-373
  CrossrefPubMedGoogle Scholar
• 44 Rowinsky E K, Eisenhauer E A, Chaudhry V. et al . Clinical toxicities encountered with paclitaxel (Taxol).  Semin Oncol. 1993;  20 1-15
  PubMedGoogle Scholar
• 45 Sahenk Z, Barohn R, New P. et al . Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings.  Arch Neurol. 1994;  51 726-729
  CrossrefPubMedGoogle Scholar
• 46 Forsyth P A, Balmaceda C, Peterson K. et al . Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.  J Neurooncol. 1997;  35 47-53
  CrossrefPubMedGoogle Scholar
• 47 Freilich R J, Balmaceda C, Seidman A D. et al . Motor neuropathy due to docetaxel and paclitaxel.  Neurology. 1996;  47 115-118
  CrossrefPubMedGoogle Scholar
• 48 Hilkens P H, Verweij J, Stoter G. et al . Peripheral neurotoxicity induced by docetaxel.  Neurology. 1996;  46 104-108
  PubMedGoogle Scholar
• 49 Iniguez C, Larrode P, Mayordomo J I. et al . Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel.  Neurology. 1998;  51 868-870
  PubMedGoogle Scholar
• 50 Bent M J, Verweij J, Doorn P A. Progression of paclitaxel induced neuropathy following dicontinuation of treatment.  Muscle Nerve. 1997;  20 750-752
  PubMedGoogle Scholar
• 51 New P Z, Jackson C E, Rinaldi D. et al . Peripheral neuropathy secondary to docetaxel (Taxotere).  Neurology. 1996;  46 108-111
  PubMedGoogle Scholar
• 52 Jerian S M, Sarosy G A, Link C J. et al . Incapacitating autonomic neuropathy precipitated by taxol.  Gynecol Oncol. 1993;  51 277-280
  CrossrefPubMedGoogle Scholar
• 53 Schiff P B, Fant J, Horwitz S B. Promotion of microtubule assembly in vitro by taxol.  Nature. 1979;  277 665-667
  CrossrefPubMedGoogle Scholar
• 54 Letourneau P C, Ressler A H. Inhibition of neurite initiation and growth by taxol.  J Cell Biol. 1984;  98 1355-1362
  CrossrefPubMedGoogle Scholar
• 55 Masurovsky E B, Peterson E R, Crain S M. et al . Microtubule arrays in taxol-treated mouse dorsal root ganglion-spinal cord cultures.  Brain Res. 1981;  217 392-398
  CrossrefPubMedGoogle Scholar
• 56 Cavaletti G, Bogliun G, Marzorati L. et al . Peripheral neurotoxicity of taxol in patients previously treated with cisplatin.  Cancer. 1995;  75 1141-1150
  CrossrefPubMedGoogle Scholar
• 57 Berger T, Malayeri R, Doppelbauer A. et al . Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.  Eur J Cancer. 1997;  33 1393-1399
  CrossrefPubMedGoogle Scholar
• 58 Armstrong J G, Dyke R W, Fouts P J. Initial clinical experience with leurocristine, a new alkaloid from Vinca rosea Linn.  Proc Am Ass Cancer Res. 1962;  3 301
  PubMedGoogle Scholar
• 59 Karon M. Leurocristine sulfate in the treatment of acute leukemia.  Proc Am Ass Cancer Res. 1962;  3 333
  PubMedGoogle Scholar
• 60 McLeod J G, Penny R. Vincristine neuropathy: an electrophysiological and histological study.  J Neurol Neurosurg Psychiatry. 1969;  32 297-304
  CrossrefPubMedGoogle Scholar
• 61 Casey E B, Jellife A M, Le Quesne P M. et al . Vincristine neuropathy. Clinical and electrophysiological observations.  Brain. 1973;  96 69-86
  CrossrefPubMedGoogle Scholar
• 62 Pal P K. Clinical and electrophysiological studies in vincristine induced neuropathy.  Electromyogr Clin Neurophysiol. 1999;  39 323-333
  PubMedGoogle Scholar
• 63 Graf W D, Chance P F, Lensch M W. et al . Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.  Cancer. 1996;  77 1356-1362
  CrossrefPubMedGoogle Scholar
• 64 Pace A, Bove L, Nistico C. et al . Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients.  J Neurol Neurosurg Psychiatry. 1996;  61 409-411
  CrossrefPubMedGoogle Scholar
• 65 Guiheneuc P, Ginet J, Groleau J Y. et al . Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dying-back phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex.  J Neurol Sci. 1980;  45 355-366
  CrossrefPubMedGoogle Scholar
• 66 Bradley W G. The neuromyopathy of vincristine in the guinea pig. An electrophysiological and pathological study.  J Neurol Sci. 1970;  10 133-162
  CrossrefPubMedGoogle Scholar
• 67 Aley K O, Reichling D B, Levine J D. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans.  Neuroscience. 1996;  73 259-265
  CrossrefPubMedGoogle Scholar
• 68 Tanner K D, Reichling D B, Levine J D. Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat.  J Neurosci. 1998;  18 6480-6491
  PubMedGoogle Scholar
• 69 Wilson L, Creswell K M, Chin D. The mechanism of action of vinblastine. Binding of (acetyl-3H)vinblastine to embryonic chick brain tubulin and tubulin from sea urchin sperm tail outer doublet microtubules.  Biochemistry. 1975;  14 5586-5592
  CrossrefPubMedGoogle Scholar
• 70 Marantz R, Ventilla M, Shelanski M. Vinblastine-induced precipitation of microtubule protein.  Science. 1969;  165 498-499
  PubMedGoogle Scholar
• 71 Schlaepfer W W. Vincristine induces axonal alterations in rat peripheral nerve.  J Neuropathol Exp Neurol. 1971;  30 488
  PubMedGoogle Scholar
• 72 Cho E S, Lowndes H E, Goldstein B D. Vincristine induces proximal giant axonal neuropathy in cats.  J Neuropathol Exp Neurol. 1980;  39 583
  PubMedGoogle Scholar
• 73 Devor M, Govrin-Lippmann R, Angelides K. Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation.  J Neurosci. 1993;  13 1976-1992
  PubMedGoogle Scholar
• 74 Oakes S G, Santone K S, Powis G. Effect of some anticancer drugs on the surface membrane electrical properties of differentiated murine neuroblastoma cells.  J Natl Cancer Inst. 1987;  79 155-161
  PubMedGoogle Scholar
• 75 Apfel S C, Arezzo J C, Lipson L. et al . Nerve growth factor prevents experimental cisplatin neuropathy.  Ann Neurol. 1992;  31 76-80
  CrossrefPubMedGoogle Scholar
• 76 Contreras P C, Vaught J L, Gruner J A. et al . Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice.  Brain Res. 1997;  774 20-26
  CrossrefPubMedGoogle Scholar
• 77 Boyle F M, Wheeler H R, Shenfield G M. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate.  J Neurooncol. 1999;  41 107-116
  CrossrefPubMedGoogle Scholar
• 78 Hayakawa K, Sobue G, Itoh T. et al . Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro.  Life Sci. 1994;  55 519-525
  CrossrefPubMedGoogle Scholar
• 79 Gispen W H, Hamers F P, Vecht C J. et al . ACTH/MSH like peptides in the treatment of cisplatin neuropathy.  J Steroid Biochem Mol Biol. 1992;  43 179-183
  CrossrefPubMedGoogle Scholar
• 80 Taylor C W, Wang L M, List A F. et al . Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.  Eur J Cancer. 1997;  33 1693-1698
  CrossrefPubMedGoogle Scholar
• 81 Markman M. Amifostine in reducing cisplatin toxicity.  Semin Oncol. 1998;  25 522-524
  PubMedGoogle Scholar
• 82 DiPaola R S, Schuchter L. Neurologic protection by amifostine.  Semin Oncol. 1999;  26 82-88
  PubMedGoogle Scholar
• 83 Planting A S, Catimel G, de Mulder P H. et al . Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.  Ann Oncol. 1999;  10 693-700
  CrossrefPubMedGoogle Scholar

J. Schattschneider

Klinik für Neurologie

Christian-Albrechts-Universität

Niemannsweg 147

24105 Kiel

Email: j.schattschneider@neurologie.uni-kiel.de